https://trial.medpath.com/news/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/news/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-ceralasertib-imfinzi-combination-fails-phase-3-lung-cancer-trial-while-enhertu-gains-fda-breakthrough-designation 2025-12-22T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-ceralasertib-imfinzi-combination-fails-phase-3-lung-cancer-trial-while-enhertu-gains-fda-breakthrough-designation 2025-12-22T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-acquires-radicava-business-from-tanabe-pharma-for-2-5-billion-to-strengthen-rare-disease-portfolio 2025-12-22T13:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-acquires-radicava-business-from-tanabe-pharma-for-2-5-billion-to-strengthen-rare-disease-portfolio 2025-12-22T13:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-biotech-initiates-phase-3b-trial-for-novel-parkinson-s-disease-treatment-ipx203 2025-12-22T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zambon-biotech-initiates-phase-3b-trial-for-novel-parkinson-s-disease-treatment-ipx203 2025-12-22T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-identifies-prostate-cancer-patients-unlikely-to-benefit-from-cabazitaxel-chemotherapy 2025-12-22T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-identifies-prostate-cancer-patients-unlikely-to-benefit-from-cabazitaxel-chemotherapy 2025-12-22T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/mondego-bio-advances-ai-designed-ptpn2-inhibitor-ze00-0388-to-phase-1-clinical-trials 2025-12-22T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mondego-bio-advances-ai-designed-ptpn2-inhibitor-ze00-0388-to-phase-1-clinical-trials 2025-12-22T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-latify-phase-iii-trial-of-ceralasertib-plus-imfinzi-fails-to-meet-primary-endpoint-in-advanced-lung-cancer 2025-12-22T09:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-latify-phase-iii-trial-of-ceralasertib-plus-imfinzi-fails-to-meet-primary-endpoint-in-advanced-lung-cancer 2025-12-22T09:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-and-neok-bio-advance-first-in-class-bispecific-adc-abl206-to-phase-1-clinical-trial 2025-12-22T09:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-and-neok-bio-advance-first-in-class-bispecific-adc-abl206-to-phase-1-clinical-trial 2025-12-22T09:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-launches-one-on-one-pre-application-meetings-to-accelerate-drug-approvals-under-1-mechanism 2025-12-22T09:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-launches-one-on-one-pre-application-meetings-to-accelerate-drug-approvals-under-1-mechanism 2025-12-22T09:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-secures-global-rights-to-novel-lrrc15-targeting-adc-in-1-06-billion-deal-with-simcere-zaiming 2025-12-22T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-secures-global-rights-to-novel-lrrc15-targeting-adc-in-1-06-billion-deal-with-simcere-zaiming 2025-12-22T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-expands-oncology-partnership-with-universite-de-montreal-and-iricor-adding-two-map-kinase-related-discovery-programs 2025-12-22T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-expands-oncology-partnership-with-universite-de-montreal-and-iricor-adding-two-map-kinase-related-discovery-programs 2025-12-22T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-advances-china-phase-3-trial-for-illuccix-while-addressing-fda-regulatory-challenges 2025-12-22T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-advances-china-phase-3-trial-for-illuccix-while-addressing-fda-regulatory-challenges 2025-12-22T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-submits-fda-pre-request-for-pl-16-viral-blocker-with-over-90-efficacy-against-respiratory-viruses 2025-12-22T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyrizon-submits-fda-pre-request-for-pl-16-viral-blocker-with-over-90-efficacy-against-respiratory-viruses 2025-12-22T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/granules-pharmaceuticals-receives-tentative-fda-approval-for-generic-adhd-treatment 2025-12-22T09:28:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granules-pharmaceuticals-receives-tentative-fda-approval-for-generic-adhd-treatment 2025-12-22T09:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/entera-bio-reports-breakthrough-in-oral-pth-therapy-for-hypoparathyroidism-with-once-daily-tablet 2025-12-22T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entera-bio-reports-breakthrough-in-oral-pth-therapy-for-hypoparathyroidism-with-once-daily-tablet 2025-12-22T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/pluri-expands-manufacturing-partnership-with-remedy-cell-achieves-clinical-grade-production-for-fibrotic-disease-therapy 2025-12-22T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluri-expands-manufacturing-partnership-with-remedy-cell-achieves-clinical-grade-production-for-fibrotic-disease-therapy 2025-12-22T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/windward-bio-secures-700m-licensing-deal-for-dual-target-bispecific-antibody-win027 2025-12-22T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windward-bio-secures-700m-licensing-deal-for-dual-target-bispecific-antibody-win027 2025-12-22T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-updates-safety-reporting-guidelines-for-bioavailability-and-bioequivalence-studies-indian-pharma-industry-responds-positively 2025-12-22T05:28:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-updates-safety-reporting-guidelines-for-bioavailability-and-bioequivalence-studies-indian-pharma-industry-responds-positively 2025-12-22T05:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-predicts-crohn-s-disease-years-before-symptoms-emerge-opening-door-to-prevention 2025-12-22T05:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-predicts-crohn-s-disease-years-before-symptoms-emerge-opening-door-to-prevention 2025-12-22T05:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-ai-discovered-drug-rec-4881-shows-promise-in-phase-1b-2-fap-trial 2025-12-22T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-ai-discovered-drug-rec-4881-shows-promise-in-phase-1b-2-fap-trial 2025-12-22T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/samyang-biopharmaceuticals-advances-mrna-therapy-for-idiopathic-pulmonary-fibrosis-using-sens-gene-delivery-platform 2025-12-22T05:28:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samyang-biopharmaceuticals-advances-mrna-therapy-for-idiopathic-pulmonary-fibrosis-using-sens-gene-delivery-platform 2025-12-22T05:28:27+00:00 hourly 0.9 https://trial.medpath.com/news/content-not-suitable-for-medical-publication 2025-12-22T05:28:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/content-not-suitable-for-medical-publication 2025-12-22T05:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/memphasys-secures-eur525000-european-supply-deal-for-felix-sperm-isolation-technology 2025-12-22T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memphasys-secures-eur525000-european-supply-deal-for-felix-sperm-isolation-technology 2025-12-22T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-real-world-study-center-to-accelerate-drug-development-in-greater-bay-area 2025-12-22T05:27:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-establishes-real-world-study-center-to-accelerate-drug-development-in-greater-bay-area 2025-12-22T05:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-advances-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome-with-promising-phase-2-results 2025-12-22T05:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-advances-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome-with-promising-phase-2-results 2025-12-22T05:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-achieves-positive-phase-3-results-for-prostate-cancer-imaging-agent-in-china 2025-12-22T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-achieves-positive-phase-3-results-for-prostate-cancer-imaging-agent-in-china 2025-12-22T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-patent-protection-for-rezenopy-highest-strength-naloxone-nasal-spray-ahead-of-q2-2026-launch 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-secures-patent-protection-for-rezenopy-highest-strength-naloxone-nasal-spray-ahead-of-q2-2026-launch 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wasatch-biolabs-partners-with-agilent-to-advance-native-read-targeted-sequencing-technology 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wasatch-biolabs-partners-with-agilent-to-advance-native-read-targeted-sequencing-technology 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-expanded-type-1-diabetes-screening-program-as-genetic-risk-tools-show-promise-for-early-detection 2025-12-21T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-expanded-type-1-diabetes-screening-program-as-genetic-risk-tools-show-promise-for-early-detection 2025-12-21T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/rna-drug-pioneer-ribobio-passes-hong-kong-ipo-hearing-with-2b-partnership-portfolio 2025-12-21T21:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-drug-pioneer-ribobio-passes-hong-kong-ipo-hearing-with-2b-partnership-portfolio 2025-12-21T21:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/zasocitinib-shows-phase-3-superiority-over-apremilast-in-dermatology-trials 2025-12-21T21:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zasocitinib-shows-phase-3-superiority-over-apremilast-in-dermatology-trials 2025-12-21T21:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-1510-shows-promising-early-cancer-data-in-combination-trial 2025-12-21T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-1510-shows-promising-early-cancer-data-in-combination-trial 2025-12-21T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-faces-59-stock-decline-following-mixed-cystic-fibrosis-trial-results 2025-12-21T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-faces-59-stock-decline-following-mixed-cystic-fibrosis-trial-results 2025-12-21T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/antisense-oligonucleotide-therapy-reverses-developmental-defects-in-spinal-muscular-atrophy-organoids 2025-12-21T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antisense-oligonucleotide-therapy-reverses-developmental-defects-in-spinal-muscular-atrophy-organoids 2025-12-21T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/t-maximum-s-allogeneic-car-t-therapy-mt027-receives-fda-clearance-for-phase-ii-glioblastoma-trial 2025-12-21T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-maximum-s-allogeneic-car-t-therapy-mt027-receives-fda-clearance-for-phase-ii-glioblastoma-trial 2025-12-21T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharma-partners-with-astrazeneca-in-2-billion-pan-kras-inhibitor-deal 2025-12-21T17:28:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-pharma-partners-with-astrazeneca-in-2-billion-pan-kras-inhibitor-deal 2025-12-21T17:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-turkish-scientist-s-lung-cancer-drug-for-clinical-trials-after-six-years-of-research 2025-12-21T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-turkish-scientist-s-lung-cancer-drug-for-clinical-trials-after-six-years-of-research 2025-12-21T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/mit-develops-needle-free-glucose-monitor-using-light-based-technology-for-diabetes-management 2025-12-21T13:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-develops-needle-free-glucose-monitor-using-light-based-technology-for-diabetes-management 2025-12-21T13:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-antivirals-nirmatrelvir-ritonavir-and-molnupiravir-show-promise-in-reducing-cardiovascular-risks 2025-12-21T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-antivirals-nirmatrelvir-ritonavir-and-molnupiravir-show-promise-in-reducing-cardiovascular-risks 2025-12-21T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-sintilimab-combination-achieves-32-7-response-rate-in-advanced-pmmr-endometrial-cancer 2025-12-21T13:29:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fruquintinib-sintilimab-combination-achieves-32-7-response-rate-in-advanced-pmmr-endometrial-cancer 2025-12-21T13:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/sarasota-memorial-hospital-launches-gene-therapy-trials-for-bladder-cancer-treatment 2025-12-21T13:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarasota-memorial-hospital-launches-gene-therapy-trials-for-bladder-cancer-treatment 2025-12-21T13:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-receives-fda-clearance-to-begin-phase-1-2-gene-therapy-trial-for-late-onset-pompe-disease 2025-12-21T05:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-receives-fda-clearance-to-begin-phase-1-2-gene-therapy-trial-for-late-onset-pompe-disease 2025-12-21T05:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-receives-fda-clearance-for-sonelokimab-bla-submission-in-hidradenitis-suppurativa-without-additional-trials 2025-12-21T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-receives-fda-clearance-for-sonelokimab-bla-submission-in-hidradenitis-suppurativa-without-additional-trials 2025-12-21T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-novel-ethyl-cellulose-injection-system-for-cervical-dysplasia-treatment 2025-12-21T05:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-novel-ethyl-cellulose-injection-system-for-cervical-dysplasia-treatment 2025-12-21T05:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/novel-sflt-1-and-paclitaxel-combination-therapy-shows-synergistic-anti-tumor-effects-in-3d-breast-cancer-models 2025-12-21T05:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-sflt-1-and-paclitaxel-combination-therapy-shows-synergistic-anti-tumor-effects-in-3d-breast-cancer-models 2025-12-21T05:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-and-merck-launch-phase-3-litespark-033-trial-testing-novel-kidney-cancer-combination-therapy 2025-12-21T05:29:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-and-merck-launch-phase-3-litespark-033-trial-testing-novel-kidney-cancer-combination-therapy 2025-12-21T05:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/zimbabwe-launches-groundbreaking-long-acting-hiv-prevention-injection-in-12-priority-districts 2025-12-21T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimbabwe-launches-groundbreaking-long-acting-hiv-prevention-injection-in-12-priority-districts 2025-12-21T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/kalaris-therapeutics-secures-50-million-funding-to-advance-th103-for-neovascular-amd-treatment 2025-12-20T21:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalaris-therapeutics-secures-50-million-funding-to-advance-th103-for-neovascular-amd-treatment 2025-12-20T21:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/multistage-malaria-vaccine-achieves-54-efficacy-in-phase-2-trial-among-malian-adults 2025-12-20T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multistage-malaria-vaccine-achieves-54-efficacy-in-phase-2-trial-among-malian-adults 2025-12-20T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-pharmaceuticals-advances-phase-3-cah-trial-despite-leadership-transition 2025-12-20T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinetics-pharmaceuticals-advances-phase-3-cah-trial-despite-leadership-transition 2025-12-20T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-viridian-therapeutics-veligrotug-for-thyroid-eye-disease 2025-12-20T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-viridian-therapeutics-veligrotug-for-thyroid-eye-disease 2025-12-20T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-regeneron-launch-real-world-studies-to-strengthen-dupilumab-s-evidence-base-across-multiple-inflammatory-conditions 2025-12-20T21:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-regeneron-launch-real-world-studies-to-strengthen-dupilumab-s-evidence-base-across-multiple-inflammatory-conditions 2025-12-20T21:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-partners-with-myriad-genetics-to-bring-advanced-cancer-risk-assessment-tests-to-india 2025-12-20T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-partners-with-myriad-genetics-to-bring-advanced-cancer-risk-assessment-tests-to-india 2025-12-20T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-strikes-historic-deal-with-u-s-government-to-provide-free-eliquis-to-medicaid-patients 2025-12-20T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-strikes-historic-deal-with-u-s-government-to-provide-free-eliquis-to-medicaid-patients 2025-12-20T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-approved-for-pbs-listing-offering-4500-monthly-savings-for-metastatic-breast-cancer-patients 2025-12-20T17:27:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tucatinib-approved-for-pbs-listing-offering-4500-monthly-savings-for-metastatic-breast-cancer-patients 2025-12-20T17:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-files-ipo-registration-for-diabetes-business-minimed-targeting-nasdaq-listing 2025-12-20T13:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-files-ipo-registration-for-diabetes-business-minimed-targeting-nasdaq-listing 2025-12-20T13:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-secures-fda-approval-for-myqorzo-breaking-bristol-myers-squibb-s-monopoly-in-hypertrophic-cardiomyopathy 2025-12-20T13:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-secures-fda-approval-for-myqorzo-breaking-bristol-myers-squibb-s-monopoly-in-hypertrophic-cardiomyopathy 2025-12-20T13:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engager-immunotherapies 2025-12-20T09:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engager-immunotherapies 2025-12-20T09:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-international-reference-pricing-models-to-reduce-medicare-drug-costs 2025-12-20T05:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-international-reference-pricing-models-to-reduce-medicare-drug-costs 2025-12-20T05:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-official-s-skepticism-triggers-disc-medicine-stock-decline-amid-bitopertin-review 2025-12-20T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-official-s-skepticism-triggers-disc-medicine-stock-decline-amid-bitopertin-review 2025-12-20T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-therapeutics-secures-10m-funding-to-advance-gaucher-disease-treatment-toward-phase-i-trials 2025-12-20T05:28:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-therapeutics-secures-10m-funding-to-advance-gaucher-disease-treatment-toward-phase-i-trials 2025-12-20T05:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-release-joint-guidelines-for-ai-in-drug-development-as-regulatory-agencies-advance-framework-for-healthcare-ai 2025-12-20T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-ema-release-joint-guidelines-for-ai-in-drug-development-as-regulatory-agencies-advance-framework-for-healthcare-ai 2025-12-20T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-precision-medicine-drive-clinical-trial-innovation-as-industry-prepares-for-2026-transformation 2025-12-20T03:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-precision-medicine-drive-clinical-trial-innovation-as-industry-prepares-for-2026-transformation 2025-12-20T03:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-qualifies-first-surrogate-endpoint-for-osteoporosis-drug-development-accelerating-clinical-trials 2025-12-20T02:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-qualifies-first-surrogate-endpoint-for-osteoporosis-drug-development-accelerating-clinical-trials 2025-12-20T02:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-secures-government-agreement-to-lower-drug-costs-and-expand-patient-access 2025-12-20T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-secures-government-agreement-to-lower-drug-costs-and-expand-patient-access 2025-12-20T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-and-partners-advance-two-major-lung-cancer-trials-targeting-kras-g12c-and-trop2-positive-tumors 2025-12-20T00:26:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-and-partners-advance-two-major-lung-cancer-trials-targeting-kras-g12c-and-trop2-positive-tumors 2025-12-20T00:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-u-s-government-agreement-to-reduce-respiratory-drug-prices-by-up-to-66-for-40-million-americans 2025-12-20T00:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-u-s-government-agreement-to-reduce-respiratory-drug-prices-by-up-to-66-for-40-million-americans 2025-12-20T00:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/trump-executive-order-reclassifies-cannabis-to-schedule-iii-opening-new-clinical-research-opportunities 2025-12-19T21:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-executive-order-reclassifies-cannabis-to-schedule-iii-opening-new-clinical-research-opportunities 2025-12-19T21:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-completes-dose-escalation-for-novel-wrn-inhibitor-ndi-219216-in-msi-h-tumors 2025-12-19T21:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-completes-dose-escalation-for-novel-wrn-inhibitor-ndi-219216-in-msi-h-tumors 2025-12-19T21:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/iba-acquires-belgian-radiochemistry-pioneer-ora-to-strengthen-nuclear-medicine-portfolio 2025-12-19T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iba-acquires-belgian-radiochemistry-pioneer-ora-to-strengthen-nuclear-medicine-portfolio 2025-12-19T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-regains-rights-to-phase-2-ready-schizophrenia-drug-after-boehringer-ingelheim-declines-licensing-option 2025-12-19T21:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-regains-rights-to-phase-2-ready-schizophrenia-drug-after-boehringer-ingelheim-declines-licensing-option 2025-12-19T21:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-direct-contracting-model-with-venture-capital-firms-to-accelerate-healthcare-innovation 2025-12-19T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-direct-contracting-model-with-venture-capital-firms-to-accelerate-healthcare-innovation 2025-12-19T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/prophase-labs-and-advanced-biological-laboratories-announce-strategic-reverse-merger-to-create-global-diagnostics-platform 2025-12-19T21:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prophase-labs-and-advanced-biological-laboratories-announce-strategic-reverse-merger-to-create-global-diagnostics-platform 2025-12-19T21:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejection-of-low-dose-atropine-sparks-industry-petition-and-calls-for-myopia-reclassification 2025-12-19T21:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejection-of-low-dose-atropine-sparks-industry-petition-and-calls-for-myopia-reclassification 2025-12-19T21:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-historic-agreement-with-u-s-government-to-expand-drug-access-and-introduce-first-oral-pcsk9-inhibitor 2025-12-19T21:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-announces-historic-agreement-with-u-s-government-to-expand-drug-access-and-introduce-first-oral-pcsk9-inhibitor 2025-12-19T21:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reaches-agreement-with-us-government-to-lower-drug-prices-and-expand-manufacturing 2025-12-19T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-reaches-agreement-with-us-government-to-lower-drug-prices-and-expand-manufacturing 2025-12-19T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/chitose-laboratory-and-fujifilm-biosciences-form-strategic-alliance-to-advance-biopharmaceutical-manufacturing 2025-12-19T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chitose-laboratory-and-fujifilm-biosciences-form-strategic-alliance-to-advance-biopharmaceutical-manufacturing 2025-12-19T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-biontech-launch-phase-1-2-trial-testing-pumitamig-in-first-line-hepatocellular-carcinoma 2025-12-19T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-biontech-launch-phase-1-2-trial-testing-pumitamig-in-first-line-hepatocellular-carcinoma 2025-12-19T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-secures-china-approval-for-bentrio-nasal-spray-in-allergic-rhinitis-market 2025-12-19T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-secures-china-approval-for-bentrio-nasal-spray-in-allergic-rhinitis-market 2025-12-19T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/presidential-executive-order-reclassifies-cannabis-accelerating-defloria-s-phase-2-autism-drug-development 2025-12-19T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/presidential-executive-order-reclassifies-cannabis-accelerating-defloria-s-phase-2-autism-drug-development 2025-12-19T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-cancer-drug-sargramostim-shows-promise-in-halting-brain-cell-death-in-alzheimer-s-disease 2025-12-19T21:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repurposed-cancer-drug-sargramostim-shows-promise-in-halting-brain-cell-death-in-alzheimer-s-disease 2025-12-19T21:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/claros-technologies-achieves-99-99-pfas-destruction-at-commercial-scale-with-clarostechuv-platform 2025-12-19T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/claros-technologies-achieves-99-99-pfas-destruction-at-commercial-scale-with-clarostechuv-platform 2025-12-19T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-receives-fda-feedback-on-belapectin-mash-cirrhosis-program-secures-10-million-financing 2025-12-19T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galectin-therapeutics-receives-fda-feedback-on-belapectin-mash-cirrhosis-program-secures-10-million-financing 2025-12-19T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-secures-major-drug-pricing-deals-with-pharmaceutical-giants-mandates-us-manufacturing-expansion 2025-12-19T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-secures-major-drug-pricing-deals-with-pharmaceutical-giants-mandates-us-manufacturing-expansion 2025-12-19T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-expands-locket-device-to-ireland-s-largest-electrophysiology-center 2025-12-19T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-expands-locket-device-to-ireland-s-largest-electrophysiology-center 2025-12-19T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-secures-regulatory-approval-for-nature-derived-psilocybin-in-phase-iib-cancer-adjustment-disorder-trial 2025-12-19T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psyence-biomed-secures-regulatory-approval-for-nature-derived-psilocybin-in-phase-iib-cancer-adjustment-disorder-trial 2025-12-19T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-acquires-amicus-therapeutics-for-4-8-billion-to-expand-rare-disease-portfolio 2025-12-19T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-acquires-amicus-therapeutics-for-4-8-billion-to-expand-rare-disease-portfolio 2025-12-19T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/niowave-expands-10-year-actinium-225-supply-agreement-with-astrazeneca-for-advanced-cancer-therapies 2025-12-19T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niowave-expands-10-year-actinium-225-supply-agreement-with-astrazeneca-for-advanced-cancer-therapies 2025-12-19T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-confirms-280m-radioligand-therapy-manufacturing-facility-in-denton-texas 2025-12-19T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-confirms-280m-radioligand-therapy-manufacturing-facility-in-denton-texas 2025-12-19T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/bimekizumab-shows-sustained-three-year-efficacy-in-hidradenitis-suppurativa-as-treatment-landscape-expands 2025-12-19T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimekizumab-shows-sustained-three-year-efficacy-in-hidradenitis-suppurativa-as-treatment-landscape-expands 2025-12-19T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-determines-andexxa-risks-outweigh-benefits-astrazeneca-to-withdraw-anticoagulant-reversal-agent 2025-12-19T17:30:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-determines-andexxa-risks-outweigh-benefits-astrazeneca-to-withdraw-anticoagulant-reversal-agent 2025-12-19T17:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-launches-major-initiative-to-improve-brain-tumour-clinical-trial-access-through-nhs-app-integration 2025-12-19T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-launches-major-initiative-to-improve-brain-tumour-clinical-trial-access-through-nhs-app-integration 2025-12-19T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/resveratrol-copper-combination-shows-promise-against-glioblastoma-in-early-clinical-trial 2025-12-19T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resveratrol-copper-combination-shows-promise-against-glioblastoma-in-early-clinical-trial 2025-12-19T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-grifols-fesilty-for-congenital-fibrinogen-deficiency-treatment 2025-12-19T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-grifols-fesilty-for-congenital-fibrinogen-deficiency-treatment 2025-12-19T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/vtv-therapeutics-initiates-phase-2-trial-of-cadisegliatin-for-type-2-diabetes-in-middle-east-and-north-africa 2025-12-19T13:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vtv-therapeutics-initiates-phase-2-trial-of-cadisegliatin-for-type-2-diabetes-in-middle-east-and-north-africa 2025-12-19T13:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-and-teva-secure-u-s-settlement-for-eylea-biosimilar-avt06-launch-in-q4-2026 2025-12-19T13:30:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-and-teva-secure-u-s-settlement-for-eylea-biosimilar-avt06-launch-in-q4-2026 2025-12-19T13:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-recommends-vueway-for-pediatric-patients-under-2-years-addressing-critical-unmet-need-in-neonatal-imaging 2025-12-19T13:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-committee-recommends-vueway-for-pediatric-patients-under-2-years-addressing-critical-unmet-need-in-neonatal-imaging 2025-12-19T13:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-st-andrews-develops-revolutionary-method-to-convert-plastic-waste-into-cancer-drug-building-blocks 2025-12-19T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-st-andrews-develops-revolutionary-method-to-convert-plastic-waste-into-cancer-drug-building-blocks 2025-12-19T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/athira-pharma-acquires-late-stage-breast-cancer-drug-lasofoxifene-in-90-million-deal 2025-12-19T09:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/athira-pharma-acquires-late-stage-breast-cancer-drug-lasofoxifene-in-90-million-deal 2025-12-19T09:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/syneron-bio-secures-nearly-100m-series-a-funding-for-macrocyclic-peptide-platform 2025-12-19T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syneron-bio-secures-nearly-100m-series-a-funding-for-macrocyclic-peptide-platform 2025-12-19T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/rezubio-secures-20-million-series-a-to-advance-novel-membrane-anchored-drug-platform-for-obesity-and-diabetes 2025-12-19T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezubio-secures-20-million-series-a-to-advance-novel-membrane-anchored-drug-platform-for-obesity-and-diabetes 2025-12-19T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-phase-ii-falkon-trial-for-ultra-rare-bone-disease-fop-fails-to-meet-primary-endpoint 2025-12-19T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-phase-ii-falkon-trial-for-ultra-rare-bone-disease-fop-fails-to-meet-primary-endpoint 2025-12-19T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-subcutaneous-pembrolizumab-formulation-developed-through-space-station-research 2025-12-19T09:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-pembrolizumab-formulation-developed-through-space-station-research 2025-12-19T09:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-s-nu-9-drug-prevents-alzheimer-s-pathology-in-pre-symptomatic-animal-model 2025-12-19T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-s-nu-9-drug-prevents-alzheimer-s-pathology-in-pre-symptomatic-animal-model 2025-12-19T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/home-based-gamma-brain-stimulation-shows-promise-for-early-alzheimer-s-disease-in-randomized-trial 2025-12-19T05:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/home-based-gamma-brain-stimulation-shows-promise-for-early-alzheimer-s-disease-in-randomized-trial 2025-12-19T05:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/trump-executive-order-accelerates-medical-cannabis-research-as-mmj-international-holdings-prepares-fda-ready-pharmaceutical-formulations 2025-12-19T05:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-executive-order-accelerates-medical-cannabis-research-as-mmj-international-holdings-prepares-fda-ready-pharmaceutical-formulations 2025-12-19T05:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/telo-genomics-launches-blood-based-mrd-study-for-multiple-myeloma-with-university-of-athens 2025-12-19T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telo-genomics-launches-blood-based-mrd-study-for-multiple-myeloma-with-university-of-athens 2025-12-19T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/meiji-seika-pharma-partners-with-mbc-biolabs-to-accelerate-drug-discovery-innovation 2025-12-19T05:28:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiji-seika-pharma-partners-with-mbc-biolabs-to-accelerate-drug-discovery-innovation 2025-12-19T05:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-research-embraces-patient-centric-innovation-through-agile-cro-partnerships-and-digital-transformation 2025-12-19T01:51:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-research-embraces-patient-centric-innovation-through-agile-cro-partnerships-and-digital-transformation 2025-12-19T01:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-launches-36-month-open-label-extension-study-for-buntanetap-in-parkinson-s-disease 2025-12-19T01:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annovis-bio-launches-36-month-open-label-extension-study-for-buntanetap-in-parkinson-s-disease 2025-12-19T01:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/neuraworx-secures-oversubscribed-seed-funding-to-advance-first-in-class-cerebrovascular-pacing-system-for-cns-disorders 2025-12-19T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraworx-secures-oversubscribed-seed-funding-to-advance-first-in-class-cerebrovascular-pacing-system-for-cns-disorders 2025-12-19T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-camp4-therapeutics-in-440m-rna-deal-for-neurodegenerative-and-kidney-diseases 2025-12-19T01:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-partners-with-camp4-therapeutics-in-440m-rna-deal-for-neurodegenerative-and-kidney-diseases 2025-12-19T01:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-tyk2-inhibitor-glpg3667-meets-primary-endpoint-in-dermatomyositis-phase-3-enabling-study 2025-12-19T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-tyk2-inhibitor-glpg3667-meets-primary-endpoint-in-dermatomyositis-phase-3-enabling-study 2025-12-19T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/cartesian-therapeutics-appoints-car-t-pioneer-adrian-bot-to-board-of-directors 2025-12-19T01:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartesian-therapeutics-appoints-car-t-pioneer-adrian-bot-to-board-of-directors 2025-12-19T01:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/larimar-therapeutics-advances-toward-q2-2026-bla-submission-for-friedreich-s-ataxia-treatment 2025-12-19T01:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larimar-therapeutics-advances-toward-q2-2026-bla-submission-for-friedreich-s-ataxia-treatment 2025-12-19T01:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-radiation-therapy-shows-promise-for-high-risk-renal-cell-carcinoma-with-vascular-invasion 2025-12-19T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-radiation-therapy-shows-promise-for-high-risk-renal-cell-carcinoma-with-vascular-invasion 2025-12-19T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-awards-1-6-million-grant-for-controversial-hepatitis-b-vaccine-study-in-guinea-bissau 2025-12-19T01:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-awards-1-6-million-grant-for-controversial-hepatitis-b-vaccine-study-in-guinea-bissau 2025-12-19T01:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-amplatzer-piccolo-delivery-system-receives-fda-clearance-for-treating-heart-defects-in-premature-infants 2025-12-19T01:28:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-amplatzer-piccolo-delivery-system-receives-fda-clearance-for-treating-heart-defects-in-premature-infants 2025-12-19T01:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/werewolf-therapeutics-reports-promising-clinical-data-for-cancer-immunotherapies-advances-t-cell-engager-pipeline 2025-12-18T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/werewolf-therapeutics-reports-promising-clinical-data-for-cancer-immunotherapies-advances-t-cell-engager-pipeline 2025-12-18T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-submits-phase-iii-clinical-trial-application-for-bupizenge-in-cancer-related-oral-pain 2025-12-18T21:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncozenge-submits-phase-iii-clinical-trial-application-for-bupizenge-in-cancer-related-oral-pain 2025-12-18T21:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-and-cell-and-gene-therapy-catapult-form-strategic-partnership-to-advance-viral-vector-manufacturing 2025-12-18T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minaris-and-cell-and-gene-therapy-catapult-form-strategic-partnership-to-advance-viral-vector-manufacturing 2025-12-18T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-ceo-s-9-36-million-performance-award-tied-to-gene-therapy-regulatory-milestones 2025-12-18T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-ceo-s-9-36-million-performance-award-tied-to-gene-therapy-regulatory-milestones 2025-12-18T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-advances-lad603-from-phase-1-completion-to-phase-2-trial-for-severe-alopecia-areata 2025-12-18T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/almirall-advances-lad603-from-phase-1-completion-to-phase-2-trial-for-severe-alopecia-areata 2025-12-18T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gsk-s-exdensur-as-first-ultra-long-acting-biologic-for-severe-asthma 2025-12-18T21:29:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gsk-s-exdensur-as-first-ultra-long-acting-biologic-for-severe-asthma 2025-12-18T21:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-advances-first-oral-norovirus-antiviral-cdi-988-into-phase-1b-human-challenge-study 2025-12-18T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-advances-first-oral-norovirus-antiviral-cdi-988-into-phase-1b-human-challenge-study 2025-12-18T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/cybin-transitions-to-nasdaq-with-new-help-ticker-as-helus-pharma-advancing-phase-3-depression-treatment 2025-12-18T17:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybin-transitions-to-nasdaq-with-new-help-ticker-as-helus-pharma-advancing-phase-3-depression-treatment 2025-12-18T17:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-and-natera-launch-phase-3-trial-testing-zanzalintinib-in-mrd-positive-colorectal-cancer-patients 2025-12-18T17:44:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-and-natera-launch-phase-3-trial-testing-zanzalintinib-in-mrd-positive-colorectal-cancer-patients 2025-12-18T17:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/actinogen-completes-enrollment-in-pivotal-alzheimer-s-trial-with-247-participants 2025-12-18T17:40:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinogen-completes-enrollment-in-pivotal-alzheimer-s-trial-with-247-participants 2025-12-18T17:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/aztreonam-avibactam-shows-noninferior-efficacy-against-carbapenem-resistant-infections-in-open-label-trial 2025-12-18T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aztreonam-avibactam-shows-noninferior-efficacy-against-carbapenem-resistant-infections-in-open-label-trial 2025-12-18T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-zwitterionic-lipids-reduce-mrna-vaccine-inflammation-while-boosting-antigen-expression 2025-12-18T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-zwitterionic-lipids-reduce-mrna-vaccine-inflammation-while-boosting-antigen-expression 2025-12-18T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/very-low-dose-oral-immunotherapy-shows-promise-for-children-with-multiple-food-allergies 2025-12-18T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/very-low-dose-oral-immunotherapy-shows-promise-for-children-with-multiple-food-allergies 2025-12-18T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/bd-partners-with-penn-institute-to-advance-immunotherapy-research-through-high-parameter-flow-cytometry 2025-12-18T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-partners-with-penn-institute-to-advance-immunotherapy-research-through-high-parameter-flow-cytometry 2025-12-18T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-54-3-million-cepi-funding-for-first-mrna-bird-flu-vaccine-pivotal-trial 2025-12-18T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-secures-54-3-million-cepi-funding-for-first-mrna-bird-flu-vaccine-pivotal-trial 2025-12-18T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-of-azathioprine-fails-to-meet-primary-endpoint-in-early-parkinson-s-disease 2025-12-18T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-of-azathioprine-fails-to-meet-primary-endpoint-in-early-parkinson-s-disease 2025-12-18T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-rebrands-as-decoy-therapeutics-pivots-to-ai-driven-antiviral-platform 2025-12-18T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salarius-pharmaceuticals-rebrands-as-decoy-therapeutics-pivots-to-ai-driven-antiviral-platform 2025-12-18T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/liom-achieves-breakthrough-in-non-invasive-glucose-monitoring-technology-extends-series-a-to-chf-38-million 2025-12-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liom-achieves-breakthrough-in-non-invasive-glucose-monitoring-technology-extends-series-a-to-chf-38-million 2025-12-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/pulmatrix-and-cullgen-mutually-waive-no-solicitation-clause-while-awaiting-chinese-regulatory-approval-for-merger 2025-12-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmatrix-and-cullgen-mutually-waive-no-solicitation-clause-while-awaiting-chinese-regulatory-approval-for-merger 2025-12-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-receives-7-5-million-grant-to-lead-international-autism-clinical-trials-network 2025-12-18T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-receives-7-5-million-grant-to-lead-international-autism-clinical-trials-network 2025-12-18T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-reports-promising-phase-1-results-for-novel-adc-micvo-in-head-and-neck-cancer 2025-12-18T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-reports-promising-phase-1-results-for-novel-adc-micvo-in-head-and-neck-cancer 2025-12-18T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-india-receives-cdsco-approval-for-datopotamab-deruxtecan-in-hr-positive-her2-negative-breast-cancer 2025-12-18T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-india-receives-cdsco-approval-for-datopotamab-deruxtecan-in-hr-positive-her2-negative-breast-cancer 2025-12-18T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-zasocitinib-achieves-phase-3-success-in-moderate-to-severe-plaque-psoriasis 2025-12-18T17:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-zasocitinib-achieves-phase-3-success-in-moderate-to-severe-plaque-psoriasis 2025-12-18T17:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-completes-enrollment-in-phase-3-trial-of-lumryz-for-idiopathic-hypersomnia 2025-12-18T17:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-completes-enrollment-in-phase-3-trial-of-lumryz-for-idiopathic-hypersomnia 2025-12-18T17:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/athira-pharma-secures-236-million-financing-and-exclusive-rights-to-lasofoxifene-for-esr1-mutant-metastatic-breast-cancer 2025-12-18T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/athira-pharma-secures-236-million-financing-and-exclusive-rights-to-lasofoxifene-for-esr1-mutant-metastatic-breast-cancer 2025-12-18T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-achieves-four-major-regulatory-milestones-across-diverse-pipeline-including-gene-therapy-and-generic-approvals 2025-12-18T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-achieves-four-major-regulatory-milestones-across-diverse-pipeline-including-gene-therapy-and-generic-approvals 2025-12-18T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-potravitug-receives-eu-orphan-designation-for-bk-polyomavirus-infection-in-kidney-transplant-patients 2025-12-18T17:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memo-therapeutics-potravitug-receives-eu-orphan-designation-for-bk-polyomavirus-infection-in-kidney-transplant-patients 2025-12-18T17:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-and-tessel-biosciences-partner-to-leverage-ai-curated-real-world-data-for-copd-drug-development 2025-12-18T17:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-health-and-tessel-biosciences-partner-to-leverage-ai-curated-real-world-data-for-copd-drug-development 2025-12-18T17:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/havih-envirosciences-partners-with-andhra-pradesh-government-to-establish-bsl-4-anti-infective-drug-development-facility 2025-12-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/havih-envirosciences-partners-with-andhra-pradesh-government-to-establish-bsl-4-anti-infective-drug-development-facility 2025-12-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-raises-4-3-million-to-advance-cancer-treatment-development 2025-12-18T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-raises-4-3-million-to-advance-cancer-treatment-development 2025-12-18T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/tislelizumab-plus-chemoradiotherapy-shows-superior-response-rates-in-gastric-cancer-trial 2025-12-18T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tislelizumab-plus-chemoradiotherapy-shows-superior-response-rates-in-gastric-cancer-trial 2025-12-18T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-receives-fda-fast-track-designation-for-novel-bispecific-antibody-in-hepatocellular-carcinoma 2025-12-18T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-receives-fda-fast-track-designation-for-novel-bispecific-antibody-in-hepatocellular-carcinoma 2025-12-18T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ind-and-grants-fast-track-designation-for-cbi-1214-t-cell-engager-in-colorectal-cancer 2025-12-18T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ind-and-grants-fast-track-designation-for-cbi-1214-t-cell-engager-in-colorectal-cancer 2025-12-18T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-indication-for-johnson-johnson-s-trufill-n-bca-system-in-chronic-subdural-hematoma-treatment 2025-12-18T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-indication-for-johnson-johnson-s-trufill-n-bca-system-in-chronic-subdural-hematoma-treatment 2025-12-18T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/syremis-therapeutics-launches-with-165m-series-a-to-advance-novel-mental-health-therapies 2025-12-18T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syremis-therapeutics-launches-with-165m-series-a-to-advance-novel-mental-health-therapies 2025-12-18T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/usc-launches-phase-2b-trial-of-stem-cell-retinal-implant-for-advanced-dry-age-related-macular-degeneration 2025-12-18T13:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-launches-phase-2b-trial-of-stem-cell-retinal-implant-for-advanced-dry-age-related-macular-degeneration 2025-12-18T13:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/forx-therapeutics-secures-50m-series-a-to-advance-parg-inhibitor-for-parp-resistant-cancers 2025-12-18T09:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forx-therapeutics-secures-50m-series-a-to-advance-parg-inhibitor-for-parp-resistant-cancers 2025-12-18T09:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-secures-key-u-s-patent-for-dsr-heart-failure-therapy 2025-12-18T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequana-medical-secures-key-u-s-patent-for-dsr-heart-failure-therapy 2025-12-18T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-reports-72-reduction-in-bloodstream-infections-with-defencath-in-real-world-study 2025-12-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-reports-72-reduction-in-bloodstream-infections-with-defencath-in-real-world-study 2025-12-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-nominates-cid-165-as-second-oncology-program-targeting-cyclin-d1-driven-cancers 2025-12-18T05:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circle-pharma-nominates-cid-165-as-second-oncology-program-targeting-cyclin-d1-driven-cancers 2025-12-18T05:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-presents-breakthrough-anti-fibrotic-data-for-obefazimod-at-ecco-2026-alongside-comprehensive-ulcerative-colitis-results 2025-12-18T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-presents-breakthrough-anti-fibrotic-data-for-obefazimod-at-ecco-2026-alongside-comprehensive-ulcerative-colitis-results 2025-12-18T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/prism-biolab-and-talus-bioscience-partner-to-target-previously-undruggable-protein-interactions-using-ai-guided-drug-discovery 2025-12-18T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prism-biolab-and-talus-bioscience-partner-to-target-previously-undruggable-protein-interactions-using-ai-guided-drug-discovery 2025-12-18T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-in-advanced-breast-cancer 2025-12-18T05:29:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-in-advanced-breast-cancer 2025-12-18T05:29:39+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-receives-ind-approval-for-first-in-class-pd-l1-vegfr2-bispecific-adc-jskn027 2025-12-18T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamab-oncology-receives-ind-approval-for-first-in-class-pd-l1-vegfr2-bispecific-adc-jskn027 2025-12-18T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-consistent-cardiovascular-benefits-regardless-of-heart-failure-status-in-surpass-cvot-trial 2025-12-18T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-consistent-cardiovascular-benefits-regardless-of-heart-failure-status-in-surpass-cvot-trial 2025-12-18T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/heart-failure-pipeline-shows-strong-activity-with-70-companies-developing-75-therapeutic-candidates 2025-12-18T05:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-failure-pipeline-shows-strong-activity-with-70-companies-developing-75-therapeutic-candidates 2025-12-18T05:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/trump-signs-executive-order-reclassifying-cannabis-to-schedule-iii-opening-new-pathways-for-medical-research 2025-12-18T05:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-signs-executive-order-reclassifying-cannabis-to-schedule-iii-opening-new-pathways-for-medical-research 2025-12-18T05:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-advances-universal-cancer-platform-with-successful-nanoparticle-and-smart-mrna-validation 2025-12-18T01:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancervax-advances-universal-cancer-platform-with-successful-nanoparticle-and-smart-mrna-validation 2025-12-18T01:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/personalis-next-personal-test-demonstrates-ultrasensitive-ctdna-monitoring-capabilities-across-multiple-cancer-types 2025-12-18T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalis-next-personal-test-demonstrates-ultrasensitive-ctdna-monitoring-capabilities-across-multiple-cancer-types 2025-12-18T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-hmpl-a251-becomes-first-antibody-targeted-therapy-conjugate-to-enter-clinical-development 2025-12-18T01:27:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-s-hmpl-a251-becomes-first-antibody-targeted-therapy-conjugate-to-enter-clinical-development 2025-12-18T01:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-and-abbvie-extend-cancer-research-partnership-through-2027 2025-12-18T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-chicago-and-abbvie-extend-cancer-research-partnership-through-2027 2025-12-18T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-in-chronic-rhinosinusitis-after-phase-2b-trial-failure 2025-12-18T01:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-discontinues-brensocatib-development-in-chronic-rhinosinusitis-after-phase-2b-trial-failure 2025-12-18T01:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-expands-lungfit-ph-global-reach-to-39-countries-appoints-new-cfo 2025-12-17T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-expands-lungfit-ph-global-reach-to-39-countries-appoints-new-cfo 2025-12-17T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/ustekinumab-demonstrates-superior-drug-survival-among-biologic-naive-psoriasis-patients-in-large-danish-registry-study 2025-12-17T21:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ustekinumab-demonstrates-superior-drug-survival-among-biologic-naive-psoriasis-patients-in-large-danish-registry-study 2025-12-17T21:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-pharmaceuticals-announces-250m-manufacturing-expansion-to-scale-rna-interference-therapeutics-production 2025-12-17T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-pharmaceuticals-announces-250m-manufacturing-expansion-to-scale-rna-interference-therapeutics-production 2025-12-17T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/nuvectis-pharma-initiates-phase-1b-combination-study-of-nxp900-with-osimertinib-for-resistant-egfr-mutated-nsclc 2025-12-17T21:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvectis-pharma-initiates-phase-1b-combination-study-of-nxp900-with-osimertinib-for-resistant-egfr-mutated-nsclc 2025-12-17T21:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/veru-receives-fda-clarity-on-enobosarm-glp-1-combination-for-obesity-treatment-plans-phase-2b-plateau-study 2025-12-17T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-receives-fda-clarity-on-enobosarm-glp-1-combination-for-obesity-treatment-plans-phase-2b-plateau-study 2025-12-17T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapy-rejuvenates-aging-immune-systems-in-mice-boosting-vaccine-and-cancer-treatment-response 2025-12-17T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-therapy-rejuvenates-aging-immune-systems-in-mice-boosting-vaccine-and-cancer-treatment-response 2025-12-17T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-reports-positive-phase-1-results-for-cancer-immunotherapies-in-breast-and-bladder-cancer 2025-12-17T21:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-reports-positive-phase-1-results-for-cancer-immunotherapies-in-breast-and-bladder-cancer 2025-12-17T21:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/dna-nanobots-raises-3-5m-to-advance-non-viral-gene-therapy-platform-using-dna-origami-technology 2025-12-17T21:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-nanobots-raises-3-5m-to-advance-non-viral-gene-therapy-platform-using-dna-origami-technology 2025-12-17T21:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/insightec-spins-out-lotus-neuro-to-advance-focused-ultrasound-brain-therapies 2025-12-17T21:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insightec-spins-out-lotus-neuro-to-advance-focused-ultrasound-brain-therapies 2025-12-17T21:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ferumoxytol-as-novel-brain-cancer-imaging-agent-after-30-years-of-ohsu-research 2025-12-17T21:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ferumoxytol-as-novel-brain-cancer-imaging-agent-after-30-years-of-ohsu-research 2025-12-17T21:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/huxley-medical-receives-fda-clearance-for-ai-powered-central-sleep-apnea-detection-in-home-testing-device 2025-12-17T21:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huxley-medical-receives-fda-clearance-for-ai-powered-central-sleep-apnea-detection-in-home-testing-device 2025-12-17T21:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-merck-daiichi-sankyo-adc-after-fatal-lung-toxicity-events 2025-12-17T21:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-merck-daiichi-sankyo-adc-after-fatal-lung-toxicity-events 2025-12-17T21:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-combination-in-metastatic-breast-cancer 2025-12-17T17:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-combination-in-metastatic-breast-cancer 2025-12-17T17:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-receives-fda-clearance-for-first-in-class-oral-obesity-therapy-env-308-doses-first-patient-in-phase-1-trial 2025-12-17T17:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-receives-fda-clearance-for-first-in-class-oral-obesity-therapy-env-308-doses-first-patient-in-phase-1-trial 2025-12-17T17:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-s-ratutrelvir-shows-promise-as-ritonavir-free-covid-19-treatment-in-phase-2-trial 2025-12-17T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traws-pharma-s-ratutrelvir-shows-promise-as-ritonavir-free-covid-19-treatment-in-phase-2-trial 2025-12-17T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-hawaii-researchers-identify-strategy-to-overcome-antibody-drug-conjugate-resistance-in-breast-cancer 2025-12-17T17:39:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-hawaii-researchers-identify-strategy-to-overcome-antibody-drug-conjugate-resistance-in-breast-cancer 2025-12-17T17:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/short-course-tb-prevention-shows-promise-in-high-risk-populations-as-global-trials-advance 2025-12-17T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/short-course-tb-prevention-shows-promise-in-high-risk-populations-as-global-trials-advance 2025-12-17T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-reports-positive-phase-2a-results-for-sgx302-gel-formulation-in-mild-to-moderate-psoriasis 2025-12-17T17:37:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-reports-positive-phase-2a-results-for-sgx302-gel-formulation-in-mild-to-moderate-psoriasis 2025-12-17T17:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-s-wp1066-shows-promise-in-first-pediatric-brain-tumor-trial-warrants-phase-2-study 2025-12-17T17:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-s-wp1066-shows-promise-in-first-pediatric-brain-tumor-trial-warrants-phase-2-study 2025-12-17T17:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accelerated-cancer-drug-approvals-deliver-limited-survival-benefits-despite-20-billion-medicare-investment 2025-12-17T17:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accelerated-cancer-drug-approvals-deliver-limited-survival-benefits-despite-20-billion-medicare-investment 2025-12-17T17:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/half-dose-chemotherapy-proves-equally-effective-for-elderly-lymphoma-patients-in-real-world-study 2025-12-17T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/half-dose-chemotherapy-proves-equally-effective-for-elderly-lymphoma-patients-in-real-world-study 2025-12-17T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/decode-age-secures-1-7-million-pre-series-a-funding-to-advance-longevity-science-and-gut-microbiome-research 2025-12-17T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decode-age-secures-1-7-million-pre-series-a-funding-to-advance-longevity-science-and-gut-microbiome-research 2025-12-17T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-tnkase-for-acute-ischemic-stroke-first-new-stroke-treatment-in-nearly-27-years 2025-12-17T17:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-tnkase-for-acute-ischemic-stroke-first-new-stroke-treatment-in-nearly-27-years 2025-12-17T17:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/4dmt-reports-positive-phase-1-data-for-gene-therapy-4d-710-in-cystic-fibrosis 2025-12-17T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmt-reports-positive-phase-1-data-for-gene-therapy-4d-710-in-cystic-fibrosis 2025-12-17T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-and-secarna-partner-to-develop-ai-powered-antisense-therapies-for-rare-kidney-diseases 2025-12-17T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protalix-and-secarna-partner-to-develop-ai-powered-antisense-therapies-for-rare-kidney-diseases 2025-12-17T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-advances-ai-driven-drug-discovery-to-phase-iii-for-muscle-preservation-in-obesity-treatment 2025-12-17T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northstrive-biosciences-advances-ai-driven-drug-discovery-to-phase-iii-for-muscle-preservation-in-obesity-treatment 2025-12-17T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/pathmaker-neurosystems-receives-fda-breakthrough-device-designation-for-myoregulator-r-als-treatment 2025-12-17T17:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathmaker-neurosystems-receives-fda-breakthrough-device-designation-for-myoregulator-r-als-treatment 2025-12-17T17:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/peptinovo-biopharma-achieves-manufacturing-breakthrough-for-vitamin-e-based-cancer-prodrug-platform 2025-12-17T17:30:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptinovo-biopharma-achieves-manufacturing-breakthrough-for-vitamin-e-based-cancer-prodrug-platform 2025-12-17T17:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/updated-survival-data-from-flaura2-and-mariposa-trials-reshape-treatment-selection-in-egfr-mutated-advanced-nsclc 2025-12-17T17:28:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-survival-data-from-flaura2-and-mariposa-trials-reshape-treatment-selection-in-egfr-mutated-advanced-nsclc 2025-12-17T17:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-launches-world-s-first-ai-powered-gut-microbiome-test-for-early-autism-detection 2025-12-17T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuhk-launches-world-s-first-ai-powered-gut-microbiome-test-for-early-autism-detection 2025-12-17T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-discontinues-sgt-210-development-for-darier-disease-after-phase-1b-trial-fails-to-show-efficacy 2025-12-17T13:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sol-gel-discontinues-sgt-210-development-for-darier-disease-after-phase-1b-trial-fails-to-show-efficacy 2025-12-17T13:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-partners-with-netherlands-cancer-institute-to-develop-microbiome-therapies-for-cancer-immunotherapy 2025-12-17T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrm-health-partners-with-netherlands-cancer-institute-to-develop-microbiome-therapies-for-cancer-immunotherapy 2025-12-17T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-tree-frog-gut-bacterium-achieves-complete-tumor-elimination-in-mice-with-single-dose 2025-12-17T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-tree-frog-gut-bacterium-achieves-complete-tumor-elimination-in-mice-with-single-dose 2025-12-17T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/asg-s-beta1-becomes-first-inhaled-erectile-dysfunction-therapy-to-receive-fda-ind-approval 2025-12-17T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asg-s-beta1-becomes-first-inhaled-erectile-dysfunction-therapy-to-receive-fda-ind-approval 2025-12-17T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/crbn-gene-mutations-show-variable-impact-on-myeloma-drug-response-enabling-precision-treatment-selection 2025-12-17T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crbn-gene-mutations-show-variable-impact-on-myeloma-drug-response-enabling-precision-treatment-selection 2025-12-17T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-m-a-activity-surges-as-companies-brace-for-2026-patent-cliff 2025-12-17T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-m-a-activity-surges-as-companies-brace-for-2026-patent-cliff 2025-12-17T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-biosimilar-ranibizumab-ranluspec-receives-positive-ema-committee-opinion-for-multiple-eye-conditions 2025-12-17T09:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-s-biosimilar-ranibizumab-ranluspec-receives-positive-ema-committee-opinion-for-multiple-eye-conditions 2025-12-17T09:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-receives-eu-orphan-designation-for-rare-lung-disease-treatment 2025-12-17T09:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-efdoralprin-alfa-receives-eu-orphan-designation-for-rare-lung-disease-treatment 2025-12-17T09:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-receives-health-canada-approval-for-revyve-antimicrobial-wound-gel-spray-presents-clinical-data-at-wound-healing-conference 2025-12-17T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kane-biotech-receives-health-canada-approval-for-revyve-antimicrobial-wound-gel-spray-presents-clinical-data-at-wound-healing-conference 2025-12-17T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cosette-pharmaceuticals-launches-first-generic-cipro-hc-with-180-day-market-exclusivity 2025-12-17T05:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosette-pharmaceuticals-launches-first-generic-cipro-hc-with-180-day-market-exclusivity 2025-12-17T05:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-partners-with-bristol-myers-squibb-in-1-1-billion-multi-specific-antibody-deal 2025-12-17T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-partners-with-bristol-myers-squibb-in-1-1-billion-multi-specific-antibody-deal 2025-12-17T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-s-phase-3-trial-for-anti-gbm-disease-fails-primary-endpoint-despite-improved-dialysis-free-outcomes 2025-12-17T05:27:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-s-phase-3-trial-for-anti-gbm-disease-fails-primary-endpoint-despite-improved-dialysis-free-outcomes 2025-12-17T05:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-2026-outlook-falls-short-of-expectations-amid-patent-cliff-and-post-pandemic-transition 2025-12-17T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-2026-outlook-falls-short-of-expectations-amid-patent-cliff-and-post-pandemic-transition 2025-12-17T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-initiates-landscape-trial-for-x-linked-retinitis-pigmentosa-gene-therapy 2025-12-17T01:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-initiates-landscape-trial-for-x-linked-retinitis-pigmentosa-gene-therapy 2025-12-17T01:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/cms-reconsiders-medicare-coverage-for-tavr-in-asymptomatic-aortic-stenosis-patients-following-edwards-request 2025-12-17T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-reconsiders-medicare-coverage-for-tavr-in-asymptomatic-aortic-stenosis-patients-following-edwards-request 2025-12-17T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/aktis-oncology-pursues-200-million-ipo-to-advance-early-stage-cancer-therapies 2025-12-17T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aktis-oncology-pursues-200-million-ipo-to-advance-early-stage-cancer-therapies 2025-12-17T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/cms-narrows-medicare-coverage-for-skin-substitutes-to-18-products-impacting-wound-care-market 2025-12-17T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-narrows-medicare-coverage-for-skin-substitutes-to-18-products-impacting-wound-care-market 2025-12-17T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/pelareorep-shows-33-response-rate-in-kras-mutant-colorectal-cancer-tripling-standard-of-care-outcomes 2025-12-17T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelareorep-shows-33-response-rate-in-kras-mutant-colorectal-cancer-tripling-standard-of-care-outcomes 2025-12-17T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-shows-promise-for-inherited-retinal-disease-and-cardiac-dysfunction-in-preclinical-studies 2025-12-17T01:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-gene-therapy-shows-promise-for-inherited-retinal-disease-and-cardiac-dysfunction-in-preclinical-studies 2025-12-17T01:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-biosciences-advances-two-oncology-programs-with-key-enrollment-milestones-and-upcoming-data-readouts 2025-12-17T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-biosciences-advances-two-oncology-programs-with-key-enrollment-milestones-and-upcoming-data-readouts 2025-12-17T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-initiates-phase-3-trial-of-dual-mechanism-isocyclosporin-for-atopic-keratoconjunctivitis 2025-12-17T01:28:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dompe-initiates-phase-3-trial-of-dual-mechanism-isocyclosporin-for-atopic-keratoconjunctivitis 2025-12-17T01:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-secures-eur550-million-licensing-deal-with-norgine-for-hepatitis-delta-combination-therapy 2025-12-17T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-secures-eur550-million-licensing-deal-with-norgine-for-hepatitis-delta-combination-therapy 2025-12-17T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/exozymes-achieves-100-fold-scale-up-of-nct-production-with-99-conversion-efficiency-using-cell-free-enzyme-platform 2025-12-17T01:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exozymes-achieves-100-fold-scale-up-of-nct-production-with-99-conversion-efficiency-using-cell-free-enzyme-platform 2025-12-17T01:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-brain-tumor-warning-for-depo-provera-after-pfizer-lawsuit-pressure 2025-12-17T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-brain-tumor-warning-for-depo-provera-after-pfizer-lawsuit-pressure 2025-12-17T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/vyriad-s-vv169-in-vivo-car-t-therapy-achieves-100-tumor-clearance-in-multiple-myeloma-preclinical-studies 2025-12-16T21:36:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyriad-s-vv169-in-vivo-car-t-therapy-achieves-100-tumor-clearance-in-multiple-myeloma-preclinical-studies 2025-12-16T21:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/regenerative-medicine-advances-promise-functional-diabetes-cures-as-multiple-companies-report-clinical-progress 2025-12-16T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenerative-medicine-advances-promise-functional-diabetes-cures-as-multiple-companies-report-clinical-progress 2025-12-16T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/trethera-secures-2-7-million-nih-grant-to-evaluate-tre-515-combination-therapy-for-kras-inhibitor-resistant-lung-cancer 2025-12-16T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trethera-secures-2-7-million-nih-grant-to-evaluate-tre-515-combination-therapy-for-kras-inhibitor-resistant-lung-cancer 2025-12-16T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-partners-with-genentech-in-1-1-billion-oncology-target-discovery-collaboration 2025-12-16T21:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-partners-with-genentech-in-1-1-billion-oncology-target-discovery-collaboration 2025-12-16T21:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-rally-after-hours-on-fda-designations-and-clinical-trial-progress 2025-12-16T21:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stocks-rally-after-hours-on-fda-designations-and-clinical-trial-progress 2025-12-16T21:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-raises-100-million-through-convertible-bond-offering-to-fund-biosimilar-pipeline-expansion 2025-12-16T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-raises-100-million-through-convertible-bond-offering-to-fund-biosimilar-pipeline-expansion 2025-12-16T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/nephrology-advances-in-2025-fda-approvals-and-clinical-breakthroughs-transform-kidney-disease-treatment 2025-12-16T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nephrology-advances-in-2025-fda-approvals-and-clinical-breakthroughs-transform-kidney-disease-treatment 2025-12-16T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-once-monthly-mirikizumab-regimen-for-ulcerative-colitis-as-real-world-data-shows-early-treatment-benefits 2025-12-16T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-once-monthly-mirikizumab-regimen-for-ulcerative-colitis-as-real-world-data-shows-early-treatment-benefits 2025-12-16T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/profocal-cooled-laser-therapy-demonstrates-84-local-control-rate-in-prostate-cancer-phase-2-trial 2025-12-16T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profocal-cooled-laser-therapy-demonstrates-84-local-control-rate-in-prostate-cancer-phase-2-trial 2025-12-16T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-advances-rezpegaldesleukin-despite-mixed-phase-2b-results-in-alopecia-areata 2025-12-16T21:28:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-advances-rezpegaldesleukin-despite-mixed-phase-2b-results-in-alopecia-areata 2025-12-16T21:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-secures-multi-year-supply-agreement-for-alpha-emitting-radioisotopes-to-advance-targeted-cancer-therapies 2025-12-16T17:42:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-secures-multi-year-supply-agreement-for-alpha-emitting-radioisotopes-to-advance-targeted-cancer-therapies 2025-12-16T17:42:57+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-receives-fda-and-ema-alignment-for-phase-3-atebimetinib-trial-in-first-line-pancreatic-cancer 2025-12-16T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-receives-fda-and-ema-alignment-for-phase-3-atebimetinib-trial-in-first-line-pancreatic-cancer 2025-12-16T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/aeovian-pharmaceuticals-secures-55-million-series-b-to-advance-first-in-class-mtorc1-inhibitor-for-rare-epilepsy 2025-12-16T17:41:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aeovian-pharmaceuticals-secures-55-million-series-b-to-advance-first-in-class-mtorc1-inhibitor-for-rare-epilepsy 2025-12-16T17:41:17+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-oncology-restructures-leadership-to-advance-kras-targeted-cancer-pipeline 2025-12-16T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verastem-oncology-restructures-leadership-to-advance-kras-targeted-cancer-pipeline 2025-12-16T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-secures-global-rights-to-third-generation-egfr-tki-aumolertinib-for-lung-cancer-treatment 2025-12-16T17:38:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-secures-global-rights-to-third-generation-egfr-tki-aumolertinib-for-lung-cancer-treatment 2025-12-16T17:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-biosignals-partners-with-harmony-biosciences-to-integrate-ai-driven-eeg-technology-in-phase-3-hypersomnia-trials 2025-12-16T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-biosignals-partners-with-harmony-biosciences-to-integrate-ai-driven-eeg-technology-in-phase-3-hypersomnia-trials 2025-12-16T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-toronto-and-moderna-partner-on-next-generation-mucosal-vaccines-and-ai-driven-mrna-therapeutics 2025-12-16T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-toronto-and-moderna-partner-on-next-generation-mucosal-vaccines-and-ai-driven-mrna-therapeutics 2025-12-16T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/uk-partners-with-nobel-prize-winner-s-biotech-to-produce-cancer-therapies-from-nuclear-waste 2025-12-16T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-partners-with-nobel-prize-winner-s-biotech-to-produce-cancer-therapies-from-nuclear-waste 2025-12-16T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-completes-dosing-phase-of-sirt6-gene-therapy-trial-in-dogs-with-no-adverse-events 2025-12-16T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-completes-dosing-phase-of-sirt6-gene-therapy-trial-in-dogs-with-no-adverse-events 2025-12-16T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/ratio-therapeutics-doses-first-patients-in-phase-1-2-trial-of-fap-targeted-radiopharmaceutical-for-aggressive-sarcomas 2025-12-16T17:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ratio-therapeutics-doses-first-patients-in-phase-1-2-trial-of-fap-targeted-radiopharmaceutical-for-aggressive-sarcomas 2025-12-16T17:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/affibody-s-aby-271-radioligand-therapy-advances-to-phase-i-part-b-following-positive-safety-data-in-her2-positive-breast-cancer 2025-12-16T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affibody-s-aby-271-radioligand-therapy-advances-to-phase-i-part-b-following-positive-safety-data-in-her2-positive-breast-cancer 2025-12-16T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/evolveimmune-therapeutics-initiates-first-in-human-trial-of-evolve104-trispecific-t-cell-engager 2025-12-16T17:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolveimmune-therapeutics-initiates-first-in-human-trial-of-evolve104-trispecific-t-cell-engager 2025-12-16T17:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-pharma-receives-fda-clearance-for-first-in-class-oral-stat6-inhibitor-rex-8756-to-enter-phase-1-testing 2025-12-16T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recludix-pharma-receives-fda-clearance-for-first-in-class-oral-stat6-inhibitor-rex-8756-to-enter-phase-1-testing 2025-12-16T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-gene-therapy-developer-generation-bio-for-4-29-per-share 2025-12-16T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-acquires-gene-therapy-developer-generation-bio-for-4-29-per-share 2025-12-16T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/ember-lifesciences-raises-16-5m-series-a-to-address-35b-cold-chain-crisis-in-pharmaceutical-distribution 2025-12-16T17:34:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ember-lifesciences-raises-16-5m-series-a-to-address-35b-cold-chain-crisis-in-pharmaceutical-distribution 2025-12-16T17:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-elfabrio-for-fabry-disease-treatment-expanding-access-to-pegylated-enzyme-replacement-therapy 2025-12-16T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-elfabrio-for-fabry-disease-treatment-expanding-access-to-pegylated-enzyme-replacement-therapy 2025-12-16T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-secures-77-5-million-credit-facility-to-support-bioengineered-tissue-platform-expansion 2025-12-16T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-secures-77-5-million-credit-facility-to-support-bioengineered-tissue-platform-expansion 2025-12-16T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-7dx-trial-shows-no-survival-benefit-for-nivolumab-plus-docetaxel-in-metastatic-prostate-cancer 2025-12-16T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/checkmate-7dx-trial-shows-no-survival-benefit-for-nivolumab-plus-docetaxel-in-metastatic-prostate-cancer 2025-12-16T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-advances-dual-phase-iii-programs-with-namodenoson-and-piclidenoson 2025-12-16T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-biopharma-advances-dual-phase-iii-programs-with-namodenoson-and-piclidenoson 2025-12-16T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-expands-phase-ii-trial-for-lsalt-peptide-with-st-michael-s-hospital-ethics-approval 2025-12-16T17:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-expands-phase-ii-trial-for-lsalt-peptide-with-st-michael-s-hospital-ethics-approval 2025-12-16T17:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/ambros-therapeutics-launches-with-125m-to-advance-non-opioid-pain-drug-neridronate-for-rare-disease-crps-1 2025-12-16T17:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambros-therapeutics-launches-with-125m-to-advance-non-opioid-pain-drug-neridronate-for-rare-disease-crps-1 2025-12-16T17:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-s-muzastotug-receives-fda-fast-track-designation-for-mss-colorectal-cancer 2025-12-16T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-s-muzastotug-receives-fda-fast-track-designation-for-mss-colorectal-cancer 2025-12-16T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-licenses-tnx-4900-novel-sigma-1-receptor-antagonist-for-chronic-neuropathic-pain 2025-12-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-licenses-tnx-4900-novel-sigma-1-receptor-antagonist-for-chronic-neuropathic-pain 2025-12-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-joins-baselaunch-as-sixth-pharmaceutical-partner-in-basel-biotech-incubator 2025-12-16T17:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-joins-baselaunch-as-sixth-pharmaceutical-partner-in-basel-biotech-incubator 2025-12-16T17:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/baseline-blood-parameters-predict-bcma-car-t-therapy-outcomes-in-multiple-myeloma-patients 2025-12-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baseline-blood-parameters-predict-bcma-car-t-therapy-outcomes-in-multiple-myeloma-patients 2025-12-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-target-nanoparticle-therapy-achieves-90-neuron-survival-in-alzheimer-s-models 2025-12-16T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-target-nanoparticle-therapy-achieves-90-neuron-survival-in-alzheimer-s-models 2025-12-16T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-advances-mrna-cancer-therapeutics-with-dual-publications-in-nature-communications-and-jitc 2025-12-16T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-advances-mrna-cancer-therapeutics-with-dual-publications-in-nature-communications-and-jitc 2025-12-16T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/atom-therapeutics-launches-phase-2-trial-of-abp-745-for-atherosclerotic-cardiovascular-disease 2025-12-16T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atom-therapeutics-launches-phase-2-trial-of-abp-745-for-atherosclerotic-cardiovascular-disease 2025-12-16T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-secures-full-control-of-car-t-therapy-following-favorable-arbitration-ruling 2025-12-16T13:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogene-secures-full-control-of-car-t-therapy-following-favorable-arbitration-ruling 2025-12-16T13:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/nicox-completes-key-data-generation-for-ncx-470-glaucoma-drug-nda-submission-planned-for-h1-2026 2025-12-16T13:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicox-completes-key-data-generation-for-ncx-470-glaucoma-drug-nda-submission-planned-for-h1-2026 2025-12-16T13:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-s-ab8939-shows-promise-against-refractory-acute-myeloid-leukemia-with-novel-dual-target-mechanism 2025-12-16T09:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-s-ab8939-shows-promise-against-refractory-acute-myeloid-leukemia-with-novel-dual-target-mechanism 2025-12-16T09:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/manifold-bio-strengthens-leadership-team-with-coo-appointment-to-scale-ai-driven-drug-discovery-platform 2025-12-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manifold-bio-strengthens-leadership-team-with-coo-appointment-to-scale-ai-driven-drug-discovery-platform 2025-12-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-therapeutics-secures-first-german-approval-for-grassmuno-grass-pollen-immunotherapy 2025-12-16T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergy-therapeutics-secures-first-german-approval-for-grassmuno-grass-pollen-immunotherapy 2025-12-16T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapies-advance-through-clinical-trials-as-hmnc-s-novel-ketamine-formulation-shows-promise 2025-12-16T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychedelic-therapies-advance-through-clinical-trials-as-hmnc-s-novel-ketamine-formulation-shows-promise 2025-12-16T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/biostar-pharma-initiates-pivotal-u-s-trial-for-utidelone-in-her2-negative-breast-cancer-brain-metastases 2025-12-16T09:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostar-pharma-initiates-pivotal-u-s-trial-for-utidelone-in-her2-negative-breast-cancer-brain-metastases 2025-12-16T09:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-push-fda-to-modernize-manufacturing-regulations-to-support-us-drug-production 2025-12-16T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-push-fda-to-modernize-manufacturing-regulations-to-support-us-drug-production 2025-12-16T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/allink-biotherapeutics-raises-47m-to-advance-two-adc-programs-in-global-phase-i-trials 2025-12-16T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allink-biotherapeutics-raises-47m-to-advance-two-adc-programs-in-global-phase-i-trials 2025-12-16T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-aldeyra-s-reproxalap-dry-eye-treatment-to-march-2026 2025-12-16T05:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-timeline-for-aldeyra-s-reproxalap-dry-eye-treatment-to-march-2026 2025-12-16T05:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events 2025-12-16T05:26:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events 2025-12-16T05:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/apac-region-emerges-as-global-clinical-trial-powerhouse-with-50000-expected-studies 2025-12-16T03:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apac-region-emerges-as-global-clinical-trial-powerhouse-with-50000-expected-studies 2025-12-16T03:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-1-04-billion-license-for-adel-y01-novel-tau-targeting-alzheimer-s-therapy 2025-12-16T01:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-secures-1-04-billion-license-for-adel-y01-novel-tau-targeting-alzheimer-s-therapy 2025-12-16T01:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-reports-strong-besremi-growth-and-advances-pipeline-for-rare-blood-cancer-treatment 2025-12-16T01:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-reports-strong-besremi-growth-and-advances-pipeline-for-rare-blood-cancer-treatment 2025-12-16T01:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/attivare-therapeutics-secures-6-6-million-gates-foundation-grant-for-next-generation-malaria-vaccine 2025-12-16T01:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attivare-therapeutics-secures-6-6-million-gates-foundation-grant-for-next-generation-malaria-vaccine 2025-12-16T01:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/gensci-partners-with-rtw-investments-in-1-365-billion-deal-for-first-in-class-thyroid-autoimmune-disease-therapy 2025-12-16T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensci-partners-with-rtw-investments-in-1-365-billion-deal-for-first-in-class-thyroid-autoimmune-disease-therapy 2025-12-16T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-patient-data-requirements-for-real-world-evidence-in-medical-device-applications 2025-12-16T01:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-eliminates-patient-data-requirements-for-real-world-evidence-in-medical-device-applications 2025-12-16T01:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-secures-south-korean-patent-for-vivi-box-temperature-controlled-medication-storage-system 2025-12-16T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempramed-secures-south-korean-patent-for-vivi-box-temperature-controlled-medication-storage-system 2025-12-16T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-develop-cell-selective-mrna-therapy-platform-for-precision-cancer-treatment 2025-12-16T01:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-researchers-develop-cell-selective-mrna-therapy-platform-for-precision-cancer-treatment 2025-12-16T01:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-apd-1-conjugated-nanodrugs-show-promise-for-overcoming-pancreatic-cancer-immunotherapy-barriers 2025-12-16T01:30:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-apd-1-conjugated-nanodrugs-show-promise-for-overcoming-pancreatic-cancer-immunotherapy-barriers 2025-12-16T01:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-results-for-alopecia-areata-treatment-rezpegaldesleukin 2025-12-16T01:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-to-report-phase-2b-results-for-alopecia-areata-treatment-rezpegaldesleukin 2025-12-16T01:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cancer-vaccine-shows-25-5-month-median-progression-free-survival-in-five-year-melanoma-study 2025-12-16T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-cancer-vaccine-shows-25-5-month-median-progression-free-survival-in-five-year-melanoma-study 2025-12-16T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-initiates-rolling-bla-submission-for-renu-knee-osteoarthritis-treatment-following-fda-approval 2025-12-16T01:28:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organogenesis-initiates-rolling-bla-submission-for-renu-knee-osteoarthritis-treatment-following-fda-approval 2025-12-16T01:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/mochida-and-duchesnay-partner-to-bring-first-pregnancy-nausea-treatment-to-japan 2025-12-16T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mochida-and-duchesnay-partner-to-bring-first-pregnancy-nausea-treatment-to-japan 2025-12-16T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-real-world-data-barriers-to-accelerate-drug-and-device-approvals 2025-12-16T01:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-eliminates-real-world-data-barriers-to-accelerate-drug-and-device-approvals 2025-12-16T01:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-adds-commercial-veteran-keli-walbert-to-board-ahead-of-sanfilippo-syndrome-therapy-bla 2025-12-15T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-adds-commercial-veteran-keli-walbert-to-board-ahead-of-sanfilippo-syndrome-therapy-bla 2025-12-15T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/ophidion-and-neuronasal-form-strategic-partnership-to-advance-cns-therapeutics-for-parkinson-s-disease-and-metabolic-disorders 2025-12-15T21:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ophidion-and-neuronasal-form-strategic-partnership-to-advance-cns-therapeutics-for-parkinson-s-disease-and-metabolic-disorders 2025-12-15T21:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/cure-rare-disease-secures-7-4-million-cirm-grant-for-novel-gene-therapy-targeting-lgmd2i-r9 2025-12-15T21:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cure-rare-disease-secures-7-4-million-cirm-grant-for-novel-gene-therapy-targeting-lgmd2i-r9 2025-12-15T21:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-declines-patent-case-that-could-impact-heart-failure-drug-entresto-and-pharmaceutical-innovation 2025-12-15T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-declines-patent-case-that-could-impact-heart-failure-drug-entresto-and-pharmaceutical-innovation 2025-12-15T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-submits-abstract-for-crofelemer-trial-in-adult-short-bowel-syndrome-patients 2025-12-15T21:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-submits-abstract-for-crofelemer-trial-in-adult-short-bowel-syndrome-patients 2025-12-15T21:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-advances-two-phase-1-trials-targeting-kidney-disease-and-liver-cancer 2025-12-15T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-advances-two-phase-1-trials-targeting-kidney-disease-and-liver-cancer 2025-12-15T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-raises-175-million-to-advance-epilepsy-drug-bmb-101-through-phase-ii-trials 2025-12-15T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-raises-175-million-to-advance-epilepsy-drug-bmb-101-through-phase-ii-trials 2025-12-15T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-flibanserin-indication-for-postmenopausal-women-with-hypoactive-sexual-desire-disorder 2025-12-15T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-flibanserin-indication-for-postmenopausal-women-with-hypoactive-sexual-desire-disorder 2025-12-15T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-long-term-efficacy-of-luxturna-gene-therapy-for-inherited-retinal-disease 2025-12-15T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-long-term-efficacy-of-luxturna-gene-therapy-for-inherited-retinal-disease 2025-12-15T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-raises-300-million-in-public-offering-following-planned-acelyrin-merger 2025-12-15T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alumis-raises-300-million-in-public-offering-following-planned-acelyrin-merger 2025-12-15T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-reports-positive-phase-3-indigo-data-for-obexelimab-in-igg4-related-disease 2025-12-15T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-reports-positive-phase-3-indigo-data-for-obexelimab-in-igg4-related-disease 2025-12-15T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/cofactor-genomics-validates-rna-based-biomarker-for-nsclc-immunotherapy-response-in-1400-patient-study 2025-12-15T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cofactor-genomics-validates-rna-based-biomarker-for-nsclc-immunotherapy-response-in-1400-patient-study 2025-12-15T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/pilatus-biosciences-receives-fda-clearance-for-first-in-class-anti-cd36-metabolic-checkpoint-antibody-plt012 2025-12-15T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pilatus-biosciences-receives-fda-clearance-for-first-in-class-anti-cd36-metabolic-checkpoint-antibody-plt012 2025-12-15T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-covid-19-vaccine-shows-superior-t-cell-response-in-cll-patients-prompts-trial-design-change 2025-12-15T17:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-s-covid-19-vaccine-shows-superior-t-cell-response-in-cll-patients-prompts-trial-design-change 2025-12-15T17:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/sofie-biosciences-initiates-phase-3-trials-for-18f-fapi-74-pet-tracer-in-gastroesophageal-and-pancreatic-cancers 2025-12-15T17:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sofie-biosciences-initiates-phase-3-trials-for-18f-fapi-74-pet-tracer-in-gastroesophageal-and-pancreatic-cancers 2025-12-15T17:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-expands-dren-bio-partnership-with-1-7b-autoimmune-collaboration 2025-12-15T17:36:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-expands-dren-bio-partnership-with-1-7b-autoimmune-collaboration 2025-12-15T17:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/aviceda-s-avd-104-shows-31-reduction-in-geographic-atrophy-lesion-growth-in-phase-2b-trial 2025-12-15T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviceda-s-avd-104-shows-31-reduction-in-geographic-atrophy-lesion-growth-in-phase-2b-trial 2025-12-15T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/noom-launches-microdose-glp-1-program-for-preventive-health-and-longevity 2025-12-15T17:36:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noom-launches-microdose-glp-1-program-for-preventive-health-and-longevity 2025-12-15T17:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-appoints-sailaja-battula-as-chief-scientific-officer-to-lead-immuno-oncology-pipeline 2025-12-15T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankyra-therapeutics-appoints-sailaja-battula-as-chief-scientific-officer-to-lead-immuno-oncology-pipeline 2025-12-15T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/abpro-and-celltrion-submit-ind-application-for-her2-targeting-t-cell-engager-abp-102-ct-p72 2025-12-15T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpro-and-celltrion-submit-ind-application-for-her2-targeting-t-cell-engager-abp-102-ct-p72 2025-12-15T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promise-for-hereditary-spastic-paraplegia-in-preclinical-study 2025-12-15T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-shows-promise-for-hereditary-spastic-paraplegia-in-preclinical-study 2025-12-15T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/algia-pharma-receives-fda-support-for-non-opioid-pain-treatment-algiapak-to-enter-phase-2-trials 2025-12-15T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algia-pharma-receives-fda-support-for-non-opioid-pain-treatment-algiapak-to-enter-phase-2-trials 2025-12-15T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/cgt-catapult-launches-recell-consortium-to-develop-universal-safety-tests-for-cell-therapies 2025-12-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgt-catapult-launches-recell-consortium-to-develop-universal-safety-tests-for-cell-therapies 2025-12-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-roxadustat-for-myelodysplastic-syndromes-treatment 2025-12-15T17:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-roxadustat-for-myelodysplastic-syndromes-treatment 2025-12-15T17:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/immusoft-receives-fda-orphan-drug-designation-for-engineered-b-cell-therapy-isp-002-in-hunter-syndrome 2025-12-15T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immusoft-receives-fda-orphan-drug-designation-for-engineered-b-cell-therapy-isp-002-in-hunter-syndrome 2025-12-15T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/netramark-secures-phase-3-contract-following-fda-milestone-for-ai-powered-clinical-trial-platform 2025-12-15T17:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/netramark-secures-phase-3-contract-following-fda-milestone-for-ai-powered-clinical-trial-platform 2025-12-15T17:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-compounds-cbd-and-thc-show-promise-against-ovarian-cancer-in-laboratory-study 2025-12-15T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-compounds-cbd-and-thc-show-promise-against-ovarian-cancer-in-laboratory-study 2025-12-15T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-partners-with-pfizer-in-890m-tcr-discovery-deal-for-rheumatoid-arthritis 2025-12-15T17:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-partners-with-pfizer-in-890m-tcr-discovery-deal-for-rheumatoid-arthritis 2025-12-15T17:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/chai-discovery-raises-130m-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-12-15T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chai-discovery-raises-130m-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-12-15T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-completes-first-cohort-of-phase-1-trial-for-novel-inhbe-targeting-sirna-obesity-treatment 2025-12-15T17:30:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rona-therapeutics-completes-first-cohort-of-phase-1-trial-for-novel-inhbe-targeting-sirna-obesity-treatment 2025-12-15T17:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-reports-positive-phase-ii-results-for-elraglusib-in-advanced-salivary-gland-cancers 2025-12-15T17:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-reports-positive-phase-ii-results-for-elraglusib-in-advanced-salivary-gland-cancers 2025-12-15T17:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-applied-biosolutions-expands-strategic-partnerships-to-accelerate-commercial-growth-of-recombinant-protein-portfolio 2025-12-15T17:29:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyadic-applied-biosolutions-expands-strategic-partnerships-to-accelerate-commercial-growth-of-recombinant-protein-portfolio 2025-12-15T17:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-expands-protein-interactomics-platform-to-south-korea-through-strategic-distribution-partnership 2025-12-15T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-expands-protein-interactomics-platform-to-south-korea-through-strategic-distribution-partnership 2025-12-15T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-s-jak1-inhibitor-povorcitinib-receives-breakthrough-therapy-designation-for-vitiligo-treatment 2025-12-15T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-s-jak1-inhibitor-povorcitinib-receives-breakthrough-therapy-designation-for-vitiligo-treatment 2025-12-15T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/kenai-therapeutics-initiates-first-in-human-trial-of-rndp-001-neuron-replacement-therapy-for-parkinson-s-disease 2025-12-15T17:28:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenai-therapeutics-initiates-first-in-human-trial-of-rndp-001-neuron-replacement-therapy-for-parkinson-s-disease 2025-12-15T17:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-completes-phase-2-enrollment-for-novel-microneedle-basal-cell-carcinoma-treatment 2025-12-15T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-completes-phase-2-enrollment-for-novel-microneedle-basal-cell-carcinoma-treatment 2025-12-15T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-posterior-motion-preserving-spinal-device-for-degenerative-disc-disease 2025-12-15T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-posterior-motion-preserving-spinal-device-for-degenerative-disc-disease 2025-12-15T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-nephrodite-s-holly-implantable-dialysis-system 2025-12-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-nephrodite-s-holly-implantable-dialysis-system 2025-12-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-in-overcoming-venetoclax-resistance-in-chronic-lymphocytic-leukemia 2025-12-15T17:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-opaganib-shows-promise-in-overcoming-venetoclax-resistance-in-chronic-lymphocytic-leukemia 2025-12-15T17:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-submits-bla-for-imsidolimab-to-treat-rare-generalized-pustular-psoriasis 2025-12-15T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-submits-bla-for-imsidolimab-to-treat-rare-generalized-pustular-psoriasis 2025-12-15T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lerodalcibep-liga-lerochol-as-third-generation-pcsk9-inhibitor-for-cholesterol-management 2025-12-15T17:27:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lerodalcibep-liga-lerochol-as-third-generation-pcsk9-inhibitor-for-cholesterol-management 2025-12-15T17:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/link-cell-therapies-emerges-from-stealth-with-60m-series-a-to-advance-logic-gated-car-t-platform 2025-12-15T17:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/link-cell-therapies-emerges-from-stealth-with-60m-series-a-to-advance-logic-gated-car-t-platform 2025-12-15T17:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/pharmanovia-launches-first-in-class-korjuny-catumaxomab-in-germany-for-malignant-ascites-treatment 2025-12-15T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmanovia-launches-first-in-class-korjuny-catumaxomab-in-germany-for-malignant-ascites-treatment 2025-12-15T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/kyongbo-pharmaceutical-opens-korea-s-first-end-to-end-adc-cdmo-center 2025-12-15T14:42:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyongbo-pharmaceutical-opens-korea-s-first-end-to-end-adc-cdmo-center 2025-12-15T14:42:59+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-lnp-platform-delivers-liver-targeted-t-cell-engager-for-hepatocellular-carcinoma-treatment 2025-12-15T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mrna-lnp-platform-delivers-liver-targeted-t-cell-engager-for-hepatocellular-carcinoma-treatment 2025-12-15T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/macro-trial-challenges-long-standing-chronic-rhinosinusitis-treatment-paradigms 2025-12-15T14:41:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macro-trial-challenges-long-standing-chronic-rhinosinusitis-treatment-paradigms 2025-12-15T14:41:31+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-secures-commercial-agreement-with-leading-nci-cancer-center-for-divitum-tka-biomarker-test 2025-12-15T14:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovica-secures-commercial-agreement-with-leading-nci-cancer-center-for-divitum-tka-biomarker-test 2025-12-15T14:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-initiates-pivotal-phase-3-trial-of-nvd003-for-rare-pediatric-bone-condition 2025-12-15T14:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novadip-initiates-pivotal-phase-3-trial-of-nvd003-for-rare-pediatric-bone-condition 2025-12-15T14:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/atelerix-and-cherry-biotech-partner-to-enable-global-shipping-of-organoid-models-using-hydrogel-preservation-technology 2025-12-15T14:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atelerix-and-cherry-biotech-partner-to-enable-global-shipping-of-organoid-models-using-hydrogel-preservation-technology 2025-12-15T14:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-gains-fda-priority-review-for-opdivo-in-hodgkin-lymphoma 2025-12-15T14:40:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-gains-fda-priority-review-for-opdivo-in-hodgkin-lymphoma 2025-12-15T14:40:22+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-receives-fda-approval-for-generic-teriparatide-injection-challenging-eli-lilly-s-forteo-in-585m-osteoporosis-market 2025-12-15T14:40:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amphastar-receives-fda-approval-for-generic-teriparatide-injection-challenging-eli-lilly-s-forteo-in-585m-osteoporosis-market 2025-12-15T14:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-completes-phase-iii-enrollment-for-ahb-137-hepatitis-b-therapy-following-30-functional-cure-rate 2025-12-15T14:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-completes-phase-iii-enrollment-for-ahb-137-hepatitis-b-therapy-following-30-functional-cure-rate 2025-12-15T14:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/believer-meats-ceases-operations-despite-achieving-fda-and-usda-regulatory-approvals-for-cultivated-chicken 2025-12-15T14:38:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/believer-meats-ceases-operations-despite-achieving-fda-and-usda-regulatory-approvals-for-cultivated-chicken 2025-12-15T14:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-drug-screen-reveals-common-medicines-can-enhance-crispr-therapy-and-target-dna-repair-deficient-cancers 2025-12-15T14:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-drug-screen-reveals-common-medicines-can-enhance-crispr-therapy-and-target-dna-repair-deficient-cancers 2025-12-15T14:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/akums-launches-enhanced-gabapentin-er-tablets-with-retenex-technology-for-postherpetic-neuralgia-management 2025-12-15T14:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akums-launches-enhanced-gabapentin-er-tablets-with-retenex-technology-for-postherpetic-neuralgia-management 2025-12-15T14:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-pharmaceutical-receives-fda-clearance-for-phase-iii-trials-of-novel-thyroid-eye-disease-treatment 2025-12-15T14:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minghui-pharmaceutical-receives-fda-clearance-for-phase-iii-trials-of-novel-thyroid-eye-disease-treatment 2025-12-15T14:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-trial-death-raises-safety-concerns-for-brain-targeted-aav-treatments 2025-12-15T14:35:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-trial-death-raises-safety-concerns-for-brain-targeted-aav-treatments 2025-12-15T14:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-raises-3-1-million-through-warrant-exercise-to-advance-neuroplastogenic-therapeutics 2025-12-15T09:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-raises-3-1-million-through-warrant-exercise-to-advance-neuroplastogenic-therapeutics 2025-12-15T09:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-discontinues-phase-3-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease-following-futility-analysis 2025-12-15T09:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-discontinues-phase-3-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease-following-futility-analysis 2025-12-15T09:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-selected-for-korea-s-covid-19-mrna-vaccine-phase-1-clinical-trial-support-program 2025-12-15T09:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-selected-for-korea-s-covid-19-mrna-vaccine-phase-1-clinical-trial-support-program 2025-12-15T09:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-tolebrutinib-fails-phase-3-trial-in-primary-progressive-multiple-sclerosis 2025-12-15T09:30:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-tolebrutinib-fails-phase-3-trial-in-primary-progressive-multiple-sclerosis 2025-12-15T09:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/prescient-therapeutics-receives-european-approval-for-ptx-100-phase-2a-trial-in-rare-t-cell-lymphoma 2025-12-15T09:30:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prescient-therapeutics-receives-european-approval-for-ptx-100-phase-2a-trial-in-rare-t-cell-lymphoma 2025-12-15T09:30:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-crispr-cas13-rna-editing-trial-for-wet-age-related-macular-degeneration 2025-12-15T09:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-crispr-cas13-rna-editing-trial-for-wet-age-related-macular-degeneration 2025-12-15T09:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-ai-engineered-interferon-lambda-nasal-spray-for-broad-spectrum-respiratory-virus-protection 2025-12-15T09:28:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-researchers-develop-ai-engineered-interferon-lambda-nasal-spray-for-broad-spectrum-respiratory-virus-protection 2025-12-15T09:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-completes-recruitment-for-phase-3-trial-of-dmx-200-in-rare-kidney-disease-fsgs 2025-12-15T09:27:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-completes-recruitment-for-phase-3-trial-of-dmx-200-in-rare-kidney-disease-fsgs 2025-12-15T09:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/indupro-therapeutics-secures-strategic-investment-from-sanofi-for-novel-bispecific-pd-1-agonist-program 2025-12-15T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indupro-therapeutics-secures-strategic-investment-from-sanofi-for-novel-bispecific-pd-1-agonist-program 2025-12-15T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/china-mandates-rigorous-clinical-trials-for-traditional-medicine-injections-in-historic-regulatory-overhaul 2025-12-15T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-mandates-rigorous-clinical-trials-for-traditional-medicine-injections-in-historic-regulatory-overhaul 2025-12-15T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-growing-dilemma-as-10-of-approved-drugs-fail-primary-endpoints-in-pivotal-trials 2025-12-15T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-faces-growing-dilemma-as-10-of-approved-drugs-fail-primary-endpoints-in-pivotal-trials 2025-12-15T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-launches-glp-1-liraglutide-in-netherlands-marking-first-eu-direct-brand-launch 2025-12-15T09:26:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-launches-glp-1-liraglutide-in-netherlands-marking-first-eu-direct-brand-launch 2025-12-15T09:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/cynata-therapeutics-completes-enrollment-in-phase-2-trial-of-cyp-001-for-acute-graft-versus-host-disease 2025-12-15T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cynata-therapeutics-completes-enrollment-in-phase-2-trial-of-cyp-001-for-acute-graft-versus-host-disease 2025-12-15T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/immunome-prepares-to-release-phase-3-ringside-trial-results-for-varegacestat-in-desmoid-tumors 2025-12-15T01:27:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunome-prepares-to-release-phase-3-ringside-trial-results-for-varegacestat-in-desmoid-tumors 2025-12-15T01:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-initiates-clinical-study-to-expand-portable-mri-capabilities-with-contrast-enhancement 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperfine-initiates-clinical-study-to-expand-portable-mri-capabilities-with-contrast-enhancement 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-expands-rare-disease-services-through-strategic-partnership-with-curant-health 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cencora-expands-rare-disease-services-through-strategic-partnership-with-curant-health 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-therapeutics-to-report-phase-2-trial-results-for-car-t-cell-therapy-in-stiff-person-syndrome 2025-12-14T21:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyverna-therapeutics-to-report-phase-2-trial-results-for-car-t-cell-therapy-in-stiff-person-syndrome 2025-12-14T21:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/allegria-therapeutics-raises-5-1-million-to-advance-mast-cell-targeted-therapies-for-allergic-diseases 2025-12-14T21:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allegria-therapeutics-raises-5-1-million-to-advance-mast-cell-targeted-therapies-for-allergic-diseases 2025-12-14T21:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/bioretec-receives-fda-breakthrough-device-designation-for-biodegradable-remeos-drillpin 2025-12-14T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioretec-receives-fda-breakthrough-device-designation-for-biodegradable-remeos-drillpin 2025-12-14T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-initiates-phase-3-opus-trial-for-vax-31-pneumococcal-vaccine-with-strong-institutional-backing 2025-12-14T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-initiates-phase-3-opus-trial-for-vax-31-pneumococcal-vaccine-with-strong-institutional-backing 2025-12-14T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/forskolin-shows-dual-mechanism-against-aggressive-kmt2a-rearranged-acute-myeloid-leukemia 2025-12-14T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forskolin-shows-dual-mechanism-against-aggressive-kmt2a-rearranged-acute-myeloid-leukemia 2025-12-14T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-secures-tga-manufacturing-license-for-revolutionary-microarray-patch-vaccine-technology 2025-12-14T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxxas-secures-tga-manufacturing-license-for-revolutionary-microarray-patch-vaccine-technology 2025-12-14T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-discovery-identifies-novel-monkeypox-virus-drug-target-opg153 2025-12-14T13:28:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-discovery-identifies-novel-monkeypox-virus-drug-target-opg153 2025-12-14T13:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-for-glp-1-receptor-agonists-in-large-vessel-occlusion-stroke-treatment 2025-12-14T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-for-glp-1-receptor-agonists-in-large-vessel-occlusion-stroke-treatment 2025-12-14T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-lrba-targeting-approach-enhances-cancer-immunotherapy-by-inducing-ctla-4-degradation 2025-12-14T09:28:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-lrba-targeting-approach-enhances-cancer-immunotherapy-by-inducing-ctla-4-degradation 2025-12-14T09:28:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandated-to-streamline-prescription-to-otc-drug-switch-process-under-new-congressional-legislation 2025-12-14T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandated-to-streamline-prescription-to-otc-drug-switch-process-under-new-congressional-legislation 2025-12-14T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-completes-enrollment-of-90-patients-in-phase-ii-bladder-cancer-study-for-light-activated-ruvidar 2025-12-13T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-completes-enrollment-of-90-patients-in-phase-ii-bladder-cancer-study-for-light-activated-ruvidar 2025-12-13T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/d3-bio-raises-108-million-series-b-to-advance-global-phase-iii-trials-for-kras-g12c-inhibitor-elisrasib 2025-12-13T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d3-bio-raises-108-million-series-b-to-advance-global-phase-iii-trials-for-kras-g12c-inhibitor-elisrasib 2025-12-13T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-drug-pipeline-surges-with-60-therapies-from-55-companies-as-novel-mechanisms-enter-late-stage-development 2025-12-13T21:27:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-drug-pipeline-surges-with-60-therapies-from-55-companies-as-novel-mechanisms-enter-late-stage-development 2025-12-13T21:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-acquires-arthrosi-therapeutics-for-950m-to-advance-next-generation-gout-treatment 2025-12-13T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-acquires-arthrosi-therapeutics-for-950m-to-advance-next-generation-gout-treatment 2025-12-13T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-prepares-major-clinical-trial-reform-to-accelerate-drug-approvals-through-single-pivotal-studies 2025-12-13T21:26:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-prepares-major-clinical-trial-reform-to-accelerate-drug-approvals-through-single-pivotal-studies 2025-12-13T21:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-and-netherlands-reject-public-coverage-of-alzheimer-s-drug-lecanemab-despite-health-canada-approval 2025-12-13T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quebec-and-netherlands-reject-public-coverage-of-alzheimer-s-drug-lecanemab-despite-health-canada-approval 2025-12-13T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/multi-component-intranasal-covid-19-vaccine-shows-promise-in-preclinical-and-early-human-studies 2025-12-13T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-component-intranasal-covid-19-vaccine-shows-promise-in-preclinical-and-early-human-studies 2025-12-13T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-advances-exopten-manufacturing-for-first-in-human-studies-in-spinal-cord-and-optic-nerve-injuries 2025-12-13T14:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurexone-advances-exopten-manufacturing-for-first-in-human-studies-in-spinal-cord-and-optic-nerve-injuries 2025-12-13T14:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-global-settlement-for-aflibercept-biosimilar-enabling-worldwide-commercialization 2025-12-13T14:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-secures-global-settlement-for-aflibercept-biosimilar-enabling-worldwide-commercialization 2025-12-13T14:26:45+00:00 hourly 0.9